Terms ending in 2034
Every in-force patent on CureVac AG's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,117,920 | Combination of Vaccination and Inhibition of the PD-1 Pathway In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,434,158 | Combination of Vaccination and Inhibition of the PD-1 Pathway In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,458,195 | Combination of Vaccination and Inhibition of the PD-1 Pathway In force · High confidence | Curevac SE | In force | High confidence | |
| US 12,447,209 | Combination of Vaccination and Inhibition of the PD-1 Pathway In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,307,472 | Combination of Vaccination and OX40 Agonists In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,110,157 | Combination of Vaccination and OX40 Agonists In force · High confidence | Curevac SE | In force | High confidence | |
| US 9,737,595 | Combination of Vaccination and Inhibition of MHC Class I Restricted Antigen Presentation In force · High confidence | Curevac SE | In force | High confidence | |
| US 9,688,729 | Respiratory Syncytial Virus (RSV) Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,150,797 | Respiratory Syncytial Virus (RSV) Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,293,060 | Method for Increasing Expression of RNA-Encoded Proteins In force · High confidence | Curevac SE | In force | High confidence | |
| 14 more term ends in 2034 · Pro | |||||
10 of 24 patents shown. Soonest term end first, then patent number.
Pro members see all 24.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.